Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 6th January 2015
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Elanco finalises acquisition of Novartis
handshake
Elanco says it plans to significantly increase research and development.

Combined businesses involved in more than 100 development projects

Global animal health company Elanco has finalised its acquisition of Novartis Animal Health. Announcing the news yesterday, Elanco said it plans to significantly increase research and development going forward.

The purchase was announced in April last year, following the company's earlier purchase of Lohmann Animal Health. Both acquisitions position Elanco to diversify its offering.

In addition to its flagship brands, Elanco now has a broader portfolio of nearly 300 brands - including vaccines, therapeutics, antimicrobials, parasiticides and food safety.

“Elanco’s acquisition of Novartis Animal Health brings together two strong companies with a passion for serving the customer,” said Gaynor Hillier, general manager in the UK and Ireland. “We will continue to offer the products our customers trust, while significantly investing in the development of new solutions to meet our customers’ greatest unmet needs.”

Combined, the companies are working on more than 100 product development projects, focused on three key areas:

  • Enhancing care and improving quality of life for pets, as well as preventing disease and protecting from parasites
  • Protecting livestock from disease and parasites, improving animal wellbeing and reducing the environmental footprint of livestock production
  • Providing a wider set of solutions in areas such as enzymes, diagnostics, aquaculture and vaccines

Elanco, which is a division of the leading pharmaceutical company Eli Lilly and Company, also aims to help farmers around the world to produce more food using fewer resources to meet growing demands.

Complete integration of the two companies will take time but Elanco says its existing service and product availability will continue uninterrupted.

 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.